« Return to News | Clinical Intelligence

Adamis looks to test prostate cancer drug on humans

Monday, March 14, 2011 01:48 PM

Adamis Pharmaceuticals is seeking permission from federal regulators to begin testing APC-100, an experimental prostate cancer drug, on human patients for the first time, according to the San Diego Union-Tribune.

The Del Mar company’s Investigational New Drug application with the FDA seeks to recruit 30 men with castrate-resistant prostate cancer for a phase 1 trial. The testing will be conducted through the University of Wisconsin Carbone Cancer Center in Madison and Wayne State University’s Karmanos Cancer Institute in Detroit.

The oral drug, an organic molecule that was discovered by researchers at the Carbone center, is designed to block male hormones tied to prostate cancer in men who have become resistant to other hormone-blocking therapies.

In tests on mice with the disease, the drug worked 90% of the time in comparison to standard treatments that worked 55% of the time, the company said. The drug previously received a Rapid Access to Preventive Intervention Development grant from the National Cancer Institute.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.